BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $218,488 | -49.1% | 28,673 | -33.5% | 0.00% | -50.0% |
| Q3 2022 | $429,000 | +122.3% | 43,089 | +102.4% | 0.00% | +100.0% |
| Q2 2022 | $193,000 | -70.8% | 21,286 | -67.3% | 0.00% | -50.0% |
| Q1 2022 | $661,000 | +137.8% | 65,107 | +1330.3% | 0.00% | +100.0% |
| Q2 2021 | $278,000 | -92.4% | 4,552 | -92.4% | 0.00% | -93.8% |
| Q1 2021 | $3,677,000 | -62.5% | 59,698 | -56.7% | 0.02% | -62.8% |
| Q4 2020 | $9,812,000 | +110.9% | 137,985 | +11.3% | 0.04% | +138.9% |
| Q3 2020 | $4,653,000 | +21.1% | 124,022 | +5.3% | 0.02% | -5.3% |
| Q2 2020 | $3,841,000 | – | 117,785 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |